CanSino BioLogics goes public
Doctor using a laptop in the hospital, Healthcare and Medicine concept

Cansino Biologics, the developer of the Chinese coronavirus vaccine, a Tianjin-based company currently listed in Shanghai and Hong Kong, plans to sell GDRs on the Six Swiss Exchange to raise enough funds for its global expansion strategy. The application is still awaiting approval by regulators in China and Switzerland.